Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure—activity relationship study

Add time:07/13/2019    Source:sciencedirect.com

Four series of tetracyclic benzo[b]carbazolone compounds possessing more rotatable bonds and higher molecular flexibility were designed by either inserting a linker within the C8-side chain or by opening the middle ketone ring on the basis of compound 5 (Alectinib, CH5424802). Compound 15b was identified showing nearly identical high potency against both wild-type and the gatekeeper mutant ALK kinase (3.4 vs 3.9 nM). This compound has favorable PK profile with an oral bioavailability of 67.1% in rats. Moreover, compound 15b showed significant growth inhibition against ALK driven cancer cells and KARPAS-299 xenograft model.

We also recommend Trading Suppliers and Manufacturers of ethyl 10-methyl-6,11-dihydro-5H-benzo[a]carbazole-9-carboxylate (cas 5610-76-4). Pls Click Website Link as below: cas 5610-76-4 suppliers

Prev:Unusual reactivity of trifluoromethyl groups in meso-tetrakis(trifluoromethyl)porphyrin
Next:Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors)